Biovail
| Company type | Public |
|---|---|
| TSX: BVF | |
| Industry | Biotechnology Pharmaceutical |
| Founded | 1991 |
| Founder | Eugene Melnyk Rolf Reininghaus Mahmood Khan |
| Defunct | 2010 |
| Fate | Merged with Valeant Pharmaceuticals International |
| Headquarters | Mississauga, Ontario, Canada |
Area served | North America |
Key people | Dr. Douglas J.P. Squires (Chairman of the Board) William M. Wells (CEO) |
| Products | Medicine Drugs |
| Revenue | $ 757.18 million (2008) |
| $ 114.24 million (2008) | |
| $ 199.90 million (2008) | |
| Total assets | $ 1.623 billion (2008) |
| Total equity | $ 1.201 billion (2008) |
Number of employees | 1,368 - March 2009 |
| Divisions | Biovail Pharmaceuticals Canada (BPC) Biovail Contract Research (Canada) Biovail Corporation (Canada) |
| Subsidiaries | Biovail Pharmaceuticals, Inc. (BPI) (U.S.) Biovail Technologies Ltd. (U.S.) Biovail Laboratories - Dorado (Puerto Rico) Biovail Laboratories - Carolina (Puerto Rico) Biovail Laboratories International SRL (Barbados) Biovail Technologies (Ireland) Limited |
| Website | www.biovail.com |
Biovail Corporation was a Canadian pharmaceutical company, operating internationally in all aspects of pharmaceutical products. Its major production facility was located in Steinbach, Manitoba. It merged with Valeant Pharmaceuticals International in 2010.